CLINICAL EVENTS CALENDAR
Non-Accredited Education
CLINICAL EXPERIENCE WITH A NEW HYBRID CORONARY WIRE
On Demand Web ArchiveNon-Accredited
Target Audience: Physicians, nurses, and technologists.
This activity is supported by an educational grant from Terumo Medical Corporation.
Interview
Vascular Disease Management Speaks with William A. Marston, MD, RESTORE-CLI Trial Investigator
VASCULAR DISEASE MANAGEMENT 2010;7:E179–E180
_______________________________________________
What is the purpose and scope of the RESTORE- CLI trial? How many patients and centers will be involved in the Phase 3 trial, and when will it be completed?
This study is designed to evaluate the safety and efficacy of autologous tissue repair cells (TRCs) for patients with peripheral arterial disease as a treatment for critical limb ischemia (CLI). RESTORE-CLI is a Phase 2b study and will complete patient follow-up in March of 20
Interview with David Hahn, MD, Interventional Radiologist
An Interventional Radiology Laboratory’s Experience with the REEF HP PTA Balloon Catheter
Tell us about your experience with the REEF HP PTA balloon catheter.
I have had the opportunity to use the REEF HP PTA balloon catheter (Invatec, Inc., Bethlehem, Pennsylvania) since its U.S. release back in January 2010. I have been using the balloon in a busy interventional radiology lab providing the full spectrum of vascular and non-vascular interventional services in a tertiary care health system. Essentially, we needed a product that could serve as a “
CREST: Further Data Analysis Confirms Wisdom of Appropriate Patient Stratification
What can you tell us about the latest findings from the CREST trial (Carotid Revascularization Endarterectomy vs. Stenting Trial) and the further evaluation of the data?
There is now more “texture” to the data, but the conclusion is still that there are no significant differences between the outcomes with carotid artery stenting (CAS) and carotid endarterectomy (CEA). In essence, there were more minor strokes in the CAS group and more myocardial infarctions (MI) in the CEA group. Since there were three endpoints, they essentially evened out. The debates have tended t
CREST: Further Data Analysis Confirms Wisdom of Appropriate Patient Stratification
What can you tell us about the latest findings from the CREST trial (Carotid Revascularization Endarterectomy vs. Stenting Trial) and the further evaluation of the data?
There is now more “texture” to the data, but the conclusion is still that there are no significant differences between the outcomes with carotid artery stenting (CAS) and carotid endarterectomy CEA). In essence, there were more minor strokes in the CAS group and more myocardial infarctions (MI) in the CEA group. Since there were three endpoints, they essentially evened out. The debates have tended to
CREST: Further Data Analysis Confirms Wisdom of Appropriate Patient Stratification
Vascular Disease Management Speaks with CREST trial investigator, Christopher J. White, MD, FACC
What can you tell us about the latest findings from the CREST trial (Carotid Revascularization Endarterectomy vs. Stenting Trial) and the further evaluation of the data?
There is now more “texture” to the data, but the conclusion is still that there are no significant differences between the outcomes with carotid artery stenting (CAS) and carotid endarterectomy CEA). In essence, there were more minor strokes in the CAS group and more myocardial infarctions (MI
Vascular Disease Management Interviews Stephen R. Ash, MD, FACP
Please provide a brief overview of the history of kidney dialysis, particularly as it relates to vascular access techniques and management.
The concept of dialysis dates back to the start of the 20th century. It was known that you could pass blood with various chemical impurities in it, which are the type that occur with kidney disease, through cellophane membranes with a salt solution on the outside, and some of the poisons of kidney failure would pass through. Those experiments were successfully done using blood in animal kidney failure. However, the real implementation of
CREST Trial Shows CAS and CEA To Be Comparable Therapies for Stroke Prevention
Q:What do you anticipate the CREST results will show?
Rosenfield: CREST (Carotid Revascularization Endarterectomy versus Stent Trial) is a landmark trial which shows that endarterectomy and stenting for carotid artery stenosis appear to be comparable based on the primary endpoint of the trial: death, stroke and myocardial infarction. Both carotid artery stenting (CAS) and carotid endarterectomy (CEA) had remarkably low event rates and were shown to be very safe and effective stroke prevention therapies. It should be noted that this is the largest (2,522 s
The Mo.Ma® Ultra Proximal Cerebral Protection Device: An Effective New Tool
Interview with Co-Principal Investigators of the ARMOUR Trial: Gary Ansel, MD and L. Nelson Hopkins, MD
What was the purpose and scope of the ARMOUR trial? What were the trial’s
primary and secondary end points?
ANSEL: The purpose of the trial was to test a proximal protection device for carotid artery stenting (CAS) called the Mo.Ma® Ultra Proximal Cerebral Protection Device (Invatec, Inc., Bethlehem, Pennsylvania). This is a flow-clamping device to allow for CAS. The primary endpoints were MACE, which included any myocardial inf
Purcutaneous Intraspinal Navigation (PIN)
What is PIN?
PIN stands for percutaneous intraspinal navigation. Just as we’ve been using the arteries as a conduit to navigate the vascular system for a long time, we also believe it may be possible to use the space surrounding the brain and spinal cord — the so-called sub-arachnoid space — to navigate in and around the brain and spinal cord. We've known for a long time that you can access that space by putting a needle in the back. Currently, people visualize the spinal cord via myelograms and also perform lumbar punctures to draw some of the spinal fluid. Another way that peop
Vascular Disease Management talks with one of the course directors, David E. Allie, MD. 2005 marks the sixth year of this multi-
The First International CLI Summit on Lower Extremity PVD and Critical Limb Ischemia
A Pre New Cardiovascular Horizons Event
October 26-27, 2005, New Orleans Marriott, New Orleans, Louisiana
www.clisummit.com
New Cardiovascular Horizons and Management of the Diabetic Foot & Wound Healing
October 27-29, 2005, New Orleans Marriott, New Orleans, Louisiana
www.newcvhorizons.com
Can you tell us about the history and philosophy behind the New Cardiovascular Horizons meeting?
New Cardiovascular Horizons (NCVH) began in 2000 as a small, local, multi-dis
Vascular Disease Blogs
Frank J. Criado, MD, FACS, FSVM
Robert S. Dieter, MD, RVT and Aravinda Nanjundappa, MD, RVT
VDM Monthly Poll
Digital Supplements
Terumo Clinical Case Update This clinical case update was supported through an unrestricted educational grant from Terumo Medical Corporation.
Vascular Disease News Wire
- Tuesday, August 31, 2010 - 13:44
- Tuesday, August 31, 2010 - 13:41
- Tuesday, August 31, 2010 - 13:37
Anytown, California
CME Showcase
"Diabetic Peripheral Neuropathy"
Upcoming Accredited Webcast Release Date: December 22, 2008 Expiration Date: December 22, 2009 This activity is supported by an educational grant from PamLabs. To register for this Webcast, visit www.naccme.com/program/n-558/ |
REVIEW OUR OTHER
CARDIOLOGY BRANDS
Check out our other resources for healthcare professionals of all specialties.
